OTHER
5 cc 5% Dextrose solution
Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
The Effect of Perineural Dextrose Injection in Patients With Ulnar Neuropathy at the Elbow
Status
Completed
Phase
Not applicable
Enrollment
60
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
Ulnar neuropathy at the elbow (UNE) is the second most common neuropathy and occurs after recurrent or elongated elbow flexion. Diagnosis of UNE depends on clinical symptoms, physical examination, and electrophysiological findings. Imaging methods such as ultrasonography (USG) and magnetic resonance imaging show cross-sectional area and echogenicity of ulnar nerve and give information about to surrounding structures around the ulnar nerve. In mild and moderate cases, conservative treatments are administered up to 6 months, who do not benefit from conservative treatment are referred to surgery. There are not many options for conservative treatment. Activity modification, nerve gliding exercises and night splints are conservative treatment methods. Steroid injection is no longer recommended. Perineural dextrose injection is applied in tendinopathies and entrapment neuropathies (especially carpal tunnel syndrome). In the literature, there is no study showing effect of perineural dextrose injection in patients with UNE. The investigators design a randomized, double-blind, controlled trail to evaluate the effect after ultrasound-guided perineural injection with 5% dextrose in patients with UNE.
Full detailed description
After obtaining written informed consent, patients of clinically diagnosed with UNE were randomized into intervention and control group. Participants in intervention group received one-session ultrasound-guided perineural injection with 5% dextrose and control group received one-session ultrasound-guided perineural injection with normal saline. No additional treatment after injection through the study period. The primary outcome is visual analog scale (VAS) and secondary outcomes include Quick-DASH (Disabilities of Arm, Shoulder and Hand), cross-sectional area (CSA) of the ulnar nerve, motor nerve conduction velocity and distal latency of the ulnar nerve. The evaluation was performed pretreatment as well as on the 2nd week, 1st and 3rd month after the treatment.
Interventions
Treatment arms and agents.
OTHER
5 cc salin
Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
Timeline
From registration to results.
First posted
Nov 13, 2018
Study start
Nov 18, 2018
Primary completion
Jun 18, 2020
Study completion
Nov 18, 2020
Results posted
Not reported
Registry updated
Aug 23, 2022
Outcomes
What the study measures.
Primary outcomes
Change from baseline of pain on 2nd week, 1st and 3rd months after treatment: VAS
Time frame · Time Frame: Pre-treatment, 2nd week, 1st and 3rd months after treatment
Using the Visual analog scale (VAS) to measure the pain scale before treatment and multiple time frame after treatment. Recorded on a visual analogue scale (VAS), scores range from 0 to 100 mm, with higher scores indicating worse pain.
Secondary outcomes
Change from baseline in activity and functional status on 2nd week, 1st and 3rd months after treatment.
Time frame · Pre-treatment, 2nd week, 1st and 3rd months after treatment
Using the Quick-DASH to measure the activity and functional status before treatment and multiple time frame after treatment. The Quick-DASH is a shortened version of the DASH Outcome Measure. Instead of 30 items, the QuickDASH uses 11 items to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. The higher scores indicate worse functional status.
Change from baseline in cross-sectional area of the ulnar nerve on 1st and 3th months after treatment.
Time frame · Pre-treatment, 2nd week, 1st and 3rd months after treatment treatment
Using the musculoskeletal ultrasonography to measure the cross-sectional area of the ulnar nerve.
Change from baseline in motor nerve conduction velocity of the ulnar nerve
Time frame · Pre-treatment, 1st and 3rd months after treatment treatment
Using Electromyography to measure the motor nerve conduction velocity (m/sn) of the ulnar nerve
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Age between 18-65 year-old. * Neuropathic pain on the ulnar nerve distribution area for at least 1 months * Diagnosis was confirmed using an electrophysiological studies and ultrasonography Exclusion Criteria: * History of trauma to the upper extremity * Central or peripheral neurologic disease * Electromyography (EMG)-proven carpal tunnel syndrome, radiculopathy or any other neuropathy * Pregnancy or any systemic disease that might cause swelling on nerves (e.g., diabetes -mellitus, renal failure, and thyroid disease) * USG-detected bifid or trifid median nerve, persistent median artery, or space-occupying lesions
Study locations
1 registered sites.
Turkey (Türkiye). Showing up to 24 locations stored in the fast local snapshot.
Basak Mansiz-Kaplan
Ankara, Turkey (Türkiye)
Related trials
More studies on Calcitonin.
NCT IDStudyPhase / statusEnrollmentUpdated
Long-term Atogepant in Real-world Practice
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Migraine · Headache
Not applicable
Completed
513
2026-07
Different Kinematics Within a Single-File System and Postoperative Pain
Jordan University of Science and Technology · Root Canal Treatment · Postoperative Pain
Not applicable
Active, not recruiting
75
2026-07
Subcutaneous Calcitonin in Acute Herpes Zoster
Tanta University · Calcitonin · Subcutaneous
Phase 3
Recruiting
168
2026-07
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
Insel Gruppe AG, University Hospital Bern · Acute Mountain Sickness
Phase 4
Not yet recruiting
30
2026-07
Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin
Institut Claudius Regaud · Medullary Thyroid Cancer
Not applicable
Completed
24
2026-06
Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension
Rigmor Højland Jensen · Idiopathic Intracranial Hypertension (IIH)
Phase 3
Not yet recruiting
96
2026-06
i-NEED: NEw migrainE Drugs Database
IRCCS San Raffaele Roma · Episodic Migraine · Chronic Migraine
Not applicable
Recruiting
2,641
2026-06
Mulligan Mobilization and Stabilization Exercises for Sensorimotor Function in Women With Text Neck Syndrome
Pamukkale University · Neck Pain · Text Neck Syndrome
Not applicable
Completed
38
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.